Gujarat Kidney and Super Specialty IPO Day 3: GMP at 2%, subscription at 2.67x. Should you subscribe?

The Gujarat Kidney and Super Specialty IPO enters its final bidding day amid modest grey market sentiment and strong retail demand. While subscription momentum remains healthy, valuation appears stretched compared with listed peers. Analysts advise caution, highlighting execution risks, sustainability of margins and limited near-term upside despite favourable healthcare sector prospects.